SynthesisPloS one2018
The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective.
Freekje van Asten et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
50 papers cite it
this paperpooled ittrialcites it